GlassScriptPhysician profile
Christy Davis
NPI 1518925973
$1,686.92
in general payments reported to CMS, 2019-2025
30 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $220 · 2021: $339 · 2022: $134 · 2023: $65.37 · 2024: $90.50 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $243.41 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $175.14 | 2019-2020 | |
| Protega Pharmaceutials INC | $152.46 | 2025 | Roxybond |
| Glaxosmithkline, LLC. | $135.80 | 2019-2020 | |
| Abbvie INC. | $131.22 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $92.47 | 2021-2023 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.87 | 2025 | Relistor |
| Globus Medical, INC. | $84.04 | 2025 | Senza |
| Collegium Pharmaceutical, INC. | $61.25 | 2021-2023 | Xtampza |
| Amgen INC. | $58.50 | 2019-2020 | |
| Nevro Corp. | $55.69 | 2024 | Senza |
| Grt US Holding, INC. | $53.01 | 2021-2022 | |
| Lilly USA, LLC | $35.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.01 | 2019 | |
| Allergan, INC. | $30.49 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27.94 | 2019-2020 | |
| Averitas Pharma INC. | $21.89 | 2023 | Qutenza |
| Biogen, INC. | $21.70 | 2021 | |
| Medtronic, INC. | $21.07 | 2025 | Inceptiv |
| Curonix LLC | $18.91 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Phadia US INC. | $15.96 | 2019 | |
| Valinor Pharma, LLC | $15.90 | 2024 | Movantik |
| Mindray Ds USA, INC. | $15.79 | 2022 | |
| Biodelivery Sciences International, INC. | $15.36 | 2020 | |
| Hikma Pharmaceuticals USA | $15.34 | 2022 | |
| Redhill Biopharma INC. | $14.29 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.13 | 2021 | |
| Merck Sharp & Dohme LLC | $13.00 | 2019 | |
| Ibsa Pharma INC. | $12.00 | 2021 | |
| Virtus Pharmaceuticals LLC | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.